Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Fully understand and voluntarily sign informed consent. 5-15years old. At least one legal guardian and/or Subjects to sign informed consent.~* Clinically diagnosed as β-thalassemia major, phenotypes including β0β0, β+β0,βEβ0 genotype.~* Subjects with no affection with EBV, HIV, CMV, TP, HAV, HBV and HCV.~* Subjects body condition eligible for autologous stem cell transplant.~Exclusion Criteria:~* Subjects acceptable for allogeneic hematopoietic stem cell transplantation and have an available fully matched related donor.~* Active bacterial, viral, or fungal infection.~* Treated with erythropoietin prior 3 months.~* Immediate family member with any known hematological tumor.~* Subjects with severe psychiatric disorders to be unable to cooperate.~* Recently diagnosed as malaria.~* History of complex autoimmune disease.~* Persistent aspartate transaminase (AST), alanine transaminase (ALT), or total bilirubin value \>3 X the upper limit of normal (ULN).~* Subjects with severe heart, lung and kidney diseases.~* With serious iron overload, serum ferritin\>5000mg/ml.~* Any other condition that would render the subject ineligible for HSCT, as determined by the attending transplant physician or Investigator.~* Subjects who are receiving treatment from another clinical study, or have received another gene therapy.~* Subjects or guardians had resisted the guidance of the attending doctor.~* Subjects whom the investigators do not consider appropriate for participating in this clinical study.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- γ-globin reactivated autologous hematopoietic stem cells (Type: EXPERIMENTAL): each subject will accept one dose of γ-globin reactivated autologous hematopoietic stem cells

Based on this trial design, predict the completion outcome and termination type (if applicable).